Usman Azam
Board Member
Cue Biopharma, Inc. (CUE)Personal wealth note: Equibles reports source-backed professional activity and disclosed compensation; it does not estimate personal net worth.
About Usman Azam
Usman Azam is recorded as CEO and Board Member at Cue Biopharma, Inc. (CUE). Cue Biopharma, Inc. reported in an 8-K filed March 27, 2026 that Usman Azam resigned as member of the Board, effective March 26, 2026. Cue Biopharma, Inc. reported in an 8-K filed March 27, 2026 that Usman Azam resigned as President and Chief Executive Officer, effective March 26, 2026. Cue Biopharma, Inc. reported in an 8-K filed September 29, 2025 that Usman Azam was appointed member of the Board, effective September 29, 2025. Equibles holds 4 filed executive changes naming Usman Azam; each is listed under recent activity with its source filing. The proxy statement of Cue Biopharma, Inc. reports total compensation of $1,185,639 for Usman Azam in fiscal 2025, including a base salary of $143,077.
“Ms. Warren will succeed Usman Azam whose resignation as President and Chief Executive Officer and as a member of the Board was effective as of March 26, 2026 (the "Separation Date").”
“Ms. Warren will succeed Usman Azam whose resignation as President and Chief Executive Officer and as a member of the Board was effective as of March 26, 2026 (the "Separation Date").”
Summary generated from SEC filings and earnings-call records held by Equibles.
Affiliation history
Recorded current and former roles; source labels appear when available.
-
Current
2025-09-29–present
-
Current
2025-09-29–present
-
2025-09-29–2026-03-26
-
2025-09-29–2026-03-26
-
Start not stated–2026-03-26
-
Start not stated–2026-03-26
Company network
Recorded roles and call appearances connecting this person to public companies.
Leadership on record at Cue Biopharma, Inc.
Other people whose current roles at this company are on record from its filings.
- Daniel R. Passeri CEO, Board Member
- Dr. Shao-Lee Lin CEO, Board Member
- Lucinda Warren CEO, CFO
- James Ahlers CFO
- Kerri Millar CFO
- Colin G. Sandercock General Counsel
- Sumita Ray General Counsel
- Michael Meluzio Chief Accounting Officer
- Daniel Camardo Board Member
- Jill Broadfoot Board Member
Executive compensation
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Cue Biopharma, Inc. (CUE) | President and Chief Executive Officer | $143,077 | $1,185,639 |
Recent activity
Earnings-call and investor-event appearances, plus filed executive appointments or departures, newest first.